Vanguard Group Inc Acurx Pharmaceuticals, Inc. Put Options Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.42MCall Options Held
13.6KPut Options Held
4K-
Prospect Financial Services LLC Melville, NY329KShares$227,0620.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$101,0840.0% of portfolio
-
Morgan Stanley New York, NY106KShares$73,2780.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$33,3780.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$29,9910.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $7.97M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...